基质子修饰:结直肠癌中的生物标志物和潜在疗法
Xin An1, Xiaohua Lan2, Zizhen Feng2
1First College for Clinical Medicine, Guangxi Medical University, Nanning, Guangxi, China.
Annals of human genetics
|September 15, 2023
概括
基因组修饰通过表观遗传变化在结直肠癌的发展中起着关键作用. 针对这些修改为结直肠癌 (CRC) 提供了新的诊断和治疗策略.
科学领域:
- 在瘤学瘤学.
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 分子生物学分子生物学
背景情况:
- 大肠直肠癌 (CRC) 的发展涉及复杂的表观遗传修饰和改变的基因活性.
- 基因组基因修饰酶调节基因表达,对CRC进展产生关键影响.
- 基因素乙化,甲基化和酸化是CRC中研究得很好的表观遗传机制.
研究的目的:
- 详细阐述基因组修饰在CRC表观遗传调节中的作用.
- 讨论最近利用基因组修饰作为CRC的生物标志物的进展.
- 探索治疗策略,以向在CRC治疗中的组素修饰.
主要方法:
- 文献综述侧重于结直肠癌中的表观遗传机制.
- 在CRC中对基因组修饰 (乙化,甲基化,酸化) 的研究分析.
- 综合当前关于基因组修饰生物标志物和治疗方法的研究.
主要成果:
- 基因组蛋白修饰是结直肠癌表观遗传的组成部分.
- 特定的组素修饰模式与CRC的发展和进展有关.
- 向基因组修饰酶为CRC治疗提供了有前途的途径.
结论:
- 基因组蛋白修饰是结直肠癌表观遗传学的重要因素.
- 基斯基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因
- 向组素修饰为结直肠癌提供了一个有前途的治疗策略.
相关概念视频
02:30Histone Variants at the Centromere
4.4K
Histone variants are the histone proteins with structural and sequence variations. These variants may be regarded as “mutant” forms that replace their canonical histone counterparts in the nucleosomes. Specific post-translational modifications on the histone variants enable further chromatin complexity and regulate tissue-specific gene expression. The most common histone variants are from histone H2A, H2B, and linker histone H1 families. However, several variants of histone H3...
4.4K
02:32Histone Modification
3.5K
3.5K
02:25Spreading of Chromatin Modifications
8.3K
The histone proteins in the nucleosomes are post-translationally modified (PTM) to increase or decrease access to DNA. The commonly observed PTMs are methylation, acetylation, phosphorylation, and ubiquitination of lysine amino acids in the histone H3 tail region. These histone modifications have specific meaning for the cell. Hence, they are called "histone code". The protein complex involved in histone modification is termed as "reader-writer" complex.
Writers
The writer...
Writers
The writer...
8.3K
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
02:39lncRNA - Long Non-coding RNAs
8.6K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K
02:07Tumor Progression
6.4K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.4K